参考文献/References:
[1].Zulkifly H,Lip GYH,Lane DA. Epidemiology of atrial fibrillation[J]. Int J Clin Pract,2018,72(3):e13070.
[2].Lloyd-Jones DM,Wang TJ,Leip EP,et al. Lifetime risk for development of atrial fibrillation:the Framingham Heart Study[J]. Circulation,2004,110(9):1042-1046.
[3].Staerk L,Wang B,Preis SR,et al. Lifetime risk of atrial fibrillation according to optimal,borderline,or elevated levels of risk factors:cohort study based on longitudinal data from the Framingham Heart Study[J]. BMJ,2018,361:k1453.
[4].Trieb M,Kornej J,Knuplez E,et al. Atrial fibrillation is associated with alterations in HDL function,metabolism,and particle number[J]. Basic Res Cardiol,2019,114(4):27.
[5].Annoura M,Ogawa M,Kumagai K,et al. Cholesterol paradox in patients with paroxysmal atrial fibrillation[J]. Cardiology,1999,92(1):21-27.
[6].Schillaci G,Vaudo G,Reboldi G,et al. High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension[J]. J Hypertens,2001,19(12):2265-2270.
[7].Alonso A,Yin X,Roetker NS,et al. Blood lipids and the incidence of atrial fibrillation:the Multi-Ethnic Study of Atherosclerosis and the Framingham Heart Study[J]. J Am Heart Assoc,2014,3(5):e001211.
[8].Ruan ZB,Liang HX,Wang F,et al. Influencing factors of recurrence of nonvalvular atrial fibrillation after radiofrequency catheter ablation and construction of clinical nomogram prediction model[J]. Int J Clin Pract,2022,2022:8521735.
[9].Barter PJ,Nicholls S,Rye KA,et al. Antiinflammatory properties of HDL[J]. Circ Res,2004,95(8):764-772.
[10].Nofer JR,van der Giet M,T?lle M,et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3[J]. J Clin Invest,2004,113(4):569-581.
[11].Stark K,Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology[J]. Nat Rev Cardiol,2021,18(9):666-682.
[12].Wysokinski WE,Cohoon KP,Melduni RM,et al. Association between P-selectin levels and left atrial blood stasis in patients with nonvalvular atrial fibrillation[J]. Thromb Res,2018,172:4-8.
[13].Gotsch U,J?ger U,Dominis M,et al. Expression of P-selectin on endothelial cells is upregulated by LPS and TNF-alpha in vivo[J]. Cell Adhes Commun,1994,2(1):7-14.
[14].Kaseda R,Tsuchida Y,Gamboa JL,et al. Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis[J]. Nutr Metab Cardiovasc Dis,2018,28(6):582-591.
[15].Holzwirth E,Fischer-Schaepmann T,Obradovic D,et.al. Anti-inflammatory HDL effects are impaired in atrial fibrillation[J]. Heart Vessels,2022,37(1):161-171.
[16].Yu Z,Zhang D,Ji Q,et al. Inhibition of the renin-angiotensin-aldosterone system prevents and cures atrial fibrillation:An overview of systematic reviews[J]. Medicine (Baltimore),2021,100(18):e25559.
[17].Al-Seykal I,Bose A,Chevli PA,et al. Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cryoballoon ablation outcomes for paroxysmal atrial fibrillation[J]. World J Cardiol,2022,14(10):537-545.
[18].Ihara K,Sasano T. Role of inflammation in the pathogenesis of atrial fibrillation[J]. Front Physiol,2022,13:862164.
[19].Pauklin P,Zilmer M,Eha J,et al. Markers of inflammation,oxidative stress,and fibrosis in patients with atrial fibrillation[J]. Oxid Med Cell Longev,2022,2022:4556671.
[20].Minami-Takano A,Iwata H,Miyosawa K,et al. The association between impairment of HDL cholesterol efflux capacity and atrial remodeling in atrial fibrillation[J]. Sci Rep,2021,11(1):3547.
[21].Lee HJ,Lee SR, Choi EK ,et al. Low lipid levels and high variability are associated with the risk of new-onset atrial fibrillation[J]. J Am Heart Assoc,2019,8(23): e012771.
[22].Ding M,Wennberg A,Gigante B,et al. Lipid levels in midlife and risk of atrial fibrillation over 3 decades-Experience from the Swedish AMORIS cohort:a cohort study [J]. PLoS Med,2022,19(8):e1004044.
[23].Guan B,Li X,Xue W,et al. Blood lipid profiles and risk of atrial fibrillation:a systematic review and meta-analysis of cohort studies [J]. J Clin Lipidol,2020,14(1):133-142.e3.
[24].姚义松. 血脂水平和新发心房颤动的风险：系统回顾和剂量-反应Meta分析[D].重庆医科大学,2020.
[25].Harrison SL,Lane DA,Banach M,et al. LIPIDOGRAM 2015 Investigators. Lipid levels, atrial fibrillation and the impact of age:results from the LIPIDOGRAM 2015 study[J]. Atherosclerosis,2020,312:16-22.
[26].Watanabe H,Tanabe N,Yagihara N,et al. Association between lipid profile and risk of atrial fibrillation[J]. Circ J,2011,75(12):2767-2774.
[27].Tajik B,Tuomainen TP,Jarroch R,et al. Lipid levels,apolipoproteins,and risk of incident atrial fibrillation in men:a report from the Kuopio Ischaemic Heart Disease Risk Factor Study (KIHD) [J]. J Clin Lipidol,2022,16(4):447-454.
[28].Barkas F,Elisaf M,Korantzopoulos P,et al. The CHADS2 and CHA 2DS2-VASc scores predict atrial fibrillation in dyslipidemic individuals:role of incorporating low high-density lipoprotein cholesterol levels[J]. Int J Cardiol,2017,241:194-199.
[29].Li F,Du X,He L,et al. Relationship between serum lipid levels and ischemic stroke in patients with atrial fibrillation:a nested case-control study based on the China Atrial Fibrillation Registry[J]. BMC Cardiovasc Disord,2021,21(1):424.
[30].Zhong X,Jiao H,Zhao D,et al. Association between serum albumin levels and paroxysmal atrial fibrillation by gender in a Chinese population:a case-control study[J]. BMC Cardiovasc Disord,2022,22(1):387.
[31].Xue Y,Zhou Q,Shen J,et al. Lipid profile and new-onset atrial fibrillation in patients with acute st-segment elevation myocardial infarction (an observational study in southwest of China)[J]. Am J Cardiol,2019,124(10):1512-1517.
[32].Boudi FB,Kalayeh N,Movahed MR. High-density lipoprotein cholesterol(HDL-C) levels independently correlates with cardiac arrhythmias and atrial fibrillation[J]. J Intensive Care Med,2020,35(5):438-444.
[33].Liu L,Liu X,Ding X,et al. Lipid levels and new-onset atrial fibrillation in patients with acute myocardial infarction[J]. J Atheroscler Thromb,2023,30(5):515-530.
[34].Shi S,Tang Y,Zhao Q,et al. Prevalence and risk of atrial fibrillation in China:a national cross-sectional epidemiological study [J]. Lancet Reg Health West Pac,2022,23:100439.
[35].Westerman S,Wenger N. Gender differences in atrial fibrillation:a review of epidemiology,management,and outcomes[J]. Curr Cardiol Rev,2019,15(2):136-144.
[36].Kostapanos MS,Liberopoulos EN,Goudevenos JA,et al. Do statins have an antiarrhythmic activity?[J]. Cardiovasc Res ,2007,75(1):10-20.
[37].Zhang X,Xing L,Jia X,et al. Comparative lipid-lowering/increasing efficacy of 7 statins in patients with dyslipidemia,cardiovascular diseases,or diabetes mellitus:systematic review and network meta-analyses of 50 randomized controlled trials[J]. Cardiovasc Ther,2020,2020:3987065.
[38].Oraii A,Vasheghani-Farahani A,Oraii S,et al. Update on the efficacy of statins in primary and secondary prevention of atrial fibrillation[J]. Rev Port Cardiol (Engl Ed),2021,40(7):509-518.
[39].National Guideline Centre (UK). Statins for preventing atrial fibrillation after cardiothoracic surgery:atrial fibrillation:diagnosis and management:evidence review [M]. London:National Institute for Health and Care Excellence (NICE),2021,196:19-21.
[40].姬旺龙,黄晏,李宏凤,等.低CHA2DS2-VASc评分的非瓣膜性心房颤动患者左心房血栓形成危险因素分析[J].医学研究杂志,2022,51(3):113-117.
[41].景莉娟,陶海龙,李凌,等.HDL-C与非瓣膜性房颤左心房血栓形成的关系[J].郑州大学学报(医学版),2017,52(2):209-212.
[42].林碧玉,牛小伟,何涛涛,等.年龄校正D-二聚体联合HDL-C对心房颤动患者左心房血栓形成的预测价值[J].心脏杂志,2022,34(1):18-22.
[43].Canpolat U,Aytemir K,Yorgun H,et al. The role of preprocedural monocyte-to-high-density lipoprotein ratio in prediction of atrial fibrillation recurrence after cryoballoon-based catheter ablation[J]. Europace,2015,17(12):1807-1815.
[44].吴苏明,李承宗,李菲,等.心房颤动射频消融术后复发的相关因素研究[J].徐州医科大学学报,2019,39(10):707-711.
[45].张卓琦,吴苏明,李雪莲,等.血浆脂质成分对阵发性房颤射频消融术后复发的预测分析[J].中国社区医师,2019,35(31):123-124.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(10):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(10):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(10):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(10):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(10):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(10):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]邓皓月,综述,陈明,等.升高高密度脂蛋白胆固醇药物的研究进展[J].心血管病学进展,2016,(3):258.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.011]
DENG Haoyue,CHEN Ming.Advances in Elevating High-density Lipoprotein Cholesterol Drugs[J].Advances in Cardiovascular Diseases,2016,(10):258.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.011]
[8]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(10):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[9]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(10):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[10]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(10):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[11]刘力黎 陈诚 张丽敏.血脂水平与心房颤动相关性研究进展[J].心血管病学进展,2021,(6):539.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.015]
LIU Lili,CHEN Cheng,ZHANG Limin.Serum Lipid Level and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(10):539.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.015]